Hyoscyamine, methenamine, methylene blue, and sodium phosphate, monobasic,

Drug Interactions because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opioid (narcotic) analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria). Patients should be advised that the urine may become blue to blue green and the feces may be discolored as a result of the excretion of methylene blue.

Pregnancy Category C) hyoscyamine and methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether ME/NaPhos/MB/Hyo 1 Tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ME/NaPhos/MB/Hyo 1 Tablets should be given to a pregnant woman only if clearly needed. DIRECTIONS: 1 Tablet 4 times daily followed by liberal fluid intake, or as directed by a physician. FOR FULL PRODUCT INFORMATION SEE ATTACHED BOOKLET. Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to 86° F) [See USP Controlled Room Temperature]. Protect from moisture or direct sunlight.

NOTE : Patient should be advised that urine will be colored blue while taking this medication. PHARMACIST : Preserve and dispense in tight-light resistant container as defined in the USP. KEEP THIS AND ALL MEDICINES OUT OF THE REACH OF CHILDREN. Tamper evident by heat seal under cap. Do not use if there is evidence of tampering. To report an adverse event, please contact Method Pharmaceuticals, LLC at (877) 250-3427.